Luminex Begins Clinical Trials for ARIES® System and ARIES® HSV 1&2 Assay
News Mar 31, 2015
Luminex Corporation has announced that it has commenced clinical and analytical studies to evaluate the company's ARIES® System and ARIES® HSV 1&2 Assay.
"We are excited to announce the start of ARIES clinical trials as planned, which represents a key milestone in our commercial launch schedule," said Homi Shamir, President and CEO of Luminex.
Shamir continued, "Because we designed ARIES to be an easy to use solution that solves many of the problems and challenges laboratories face each day, we are highly optimistic in the market potential for this innovative platform. We continue to advance along our projected launch schedule, and expect to initiate clinical trials for additional ARIES assays in the coming months. With ARIES, we are solidifying a platform which we expect will accelerate growth for years to come."
The clinical trials are being conducted at several clinical laboratories in the U.S. and Luminex expects its FDA submission for ARIES and the HSV 1&2 Assay to occur in the summer of 2015.
Cancer Cells’ Energy Source Blocked by Natural CompoundNews
Researchers have not only untangled an unusual wiring system that cancer cells use for carbohydrate metabolism, but also identified a natural compound that appears to selectively shut down this system in laboratory studies.READ MORE
Drug Discovery Alliance Formed to Help Increase Drug Development Success RateNews
Two prominent preclinical safety companies have launched a unique European alliance to address the high safety-related failure rate in drug development.READ MORE